Dr. Leo Hong-Li Wang, MD, PhD

Dr. Wang practices at UW Medical Center - Montlake in Seattle, Washington, part of University of Washington.

Dr. Wang's NPI, 1124150156, was assigned on March 13, 2007. Dr. Wang graduated from WashU Medicine in 2005. Dr. Wang holds Washington license MD60222674.

Dr. Wang's primary practice is UW Medical Center - Montlake, at 1959 NE Pacific St Box 356151, Seattle, WA 98195 in King County. The practice phone is (206) 598-3300.

Dr. Wang's primary practice is UW Medical Center - Montlake in Seattle, Washington, part of University of Washington. The medical group on file is UW Physicians. Dmand AI also links Dr. Wang to 1 more hospital, 1 hospital outpatient department and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wang practices, 3 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Wang's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Wang is board certified in neuromuscular medicine by the American Board of Physical Medicine and Rehabilitation. Dmand AI has Dr. Wang's licenses on file in 2 states: Washington and California.

Dmand AI lists epilepsy, hereditary polyneuropathy, muscle disease and neuropathy among the conditions Dr. Wang treats.

CMS data shows 57 Medicare services from Dr. Wang across 2 procedure codes in 2024, for 39 Medicare patients. Medicare paid $4,092 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 39 Medicare patients who saw Dr. Wang in 2024. The largest group is 65 to 74, with 19 patients. 64% of them have high blood pressure, and 54% have high cholesterol. Their average risk score is 1.48, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Wang's median patient age at 54, with 54% women.

In 2024, Dr. Wang wrote 260 Medicare Part D claims for 20 patients. 56% of them were for generic drugs. CMS names the drug for 202 of them, across 8 drugs with 11 or more claims each, at $1,174,992 in total drug cost. In 2023, CMS named 115 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Wang for performance year 2024, reported through an alternative payment model (APM). Dr. Wang accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 46 papers to Dr. Wang, published from 2012 to 2025. 2016 was the busiest year, with 5. The most frequent topics are Muscle, Skeletal, Muscular Dystrophy, Facioscapulohumeral and Magnetic Resonance Imaging. Dr. Wang has published most often in Hum Mol Genet. Dr. Wang's most frequent co-authors are Stephen J. Tapscott, Dennis W. Shaw and Jeffrey M. Statland, MD.

Dmand AI links Dr. Wang to 6 clinical trials. 4 are still active or recruiting. Conditions studied include Muscular Atrophy, Spinal, Muscular Dystrophy, Facioscapulohumeral and Myositis, Inclusion Body. University of Kansas Medical Center sponsors the most, 2.

CMS Open Payments shows 45 general payments to Dr. Wang from 13 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 81% of the total. Sarepta Therapeutics, Inc. paid the most, $12,861.

Dr. Wang graduated from WashU Medicine in 2005.

Dr. Wang is in network with 17 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.